Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD16 PET-adapted first-line treatment optimization in early-stage Hodgkin lymphoma
NL-OMON47064Phase 3Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, bleomycin, vinblastine and dacarbazine in Hodgkin lymphoma (HL) (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Progression-free survival. Started Mar 2011; status: recruiting.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON47064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47064.